发明名称 Immunosuppression compound and treatment method
摘要 A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.
申请公布号 US9487786(B2) 申请公布日期 2016.11.08
申请号 US201414581485 申请日期 2014.12.23
申请人 SAREPTA THERAPEUTICS, INC. 发明人 Mourich Dan V.;Iversen Patrick L.;Weller Dwight D.
分类号 C12N15/11;A61K48/00;C07H21/02;C07H21/04;C12N15/113 主分类号 C12N15/11
代理机构 Seed IP Law Group LLP 代理人 Seed IP Law Group LLP
主权项 1. A phosphorodiamidate morpholino antisense oligonucleotide of 12 to 40 bases comprising a base sequence that is 100% complementary to contiguous bases of human CTLA-4 pre-mRNA, wherein the base sequence comprises at least 12 contiguous bases that are 100 complementary to SEQ ID NO: 22, and wherein the phosphorodiamidate morpholino antisense oligonucleotide induces skipping of exon 2 of the human CTLA-4 pre-mRNA.
地址 Corvallis OR US
您可能感兴趣的专利